**Funding antiretroviral treatment for HIV-positive temporary residents in Australia prevents transmission and is inexpensive**

Richard T. Gray\textsuperscript{A,1}, Jo Watson\textsuperscript{B}, Aaron J. Cogle\textsuperscript{B}, Don E. Smith\textsuperscript{C,D}, Jennifer F. Hoy\textsuperscript{E}, Lisa A. Bastian\textsuperscript{F}, Robert Finlayson\textsuperscript{G}, Fraser M. Drummond\textsuperscript{H}, Bill Whittaker\textsuperscript{B}, Matthew G. Law\textsuperscript{A} and Kathy Petoumenos\textsuperscript{A}

\textsuperscript{A}The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.  
\textsuperscript{B}National Association of People with HIV Australia (NAPWHA), Sydney, NSW 2042, Australia.  
\textsuperscript{C}Albion Centre, Sydney, NSW 2010, Australia.  
\textsuperscript{D}School of Public Health and Community Medicine, UNSW Sydney, Sydney, NSW 2052, Australia.  
\textsuperscript{E}Department of Infectious Diseases, The Alfred Hospital and Monash University, Melbourne Vic. 3181, Australia.  
\textsuperscript{F}Western Australian Department of Health, Perth, WA 6004, Australia.  
\textsuperscript{G}Taylor Square Private Clinic, Taylor Square, Sydney, NSW 2010, Australia.  
\textsuperscript{H}ViiV Healthcare, Abbotsford, VIC 3067, Australia.  
\textsuperscript{ICorresponding author. Email: Rgray@kirby.unsw.edu.au

**Abstract.**  
**Background:** The aim of this study is to estimate the reduction in new HIV infections and resultant cost outcomes of providing antiretroviral treatment (ART) through Australia’s ‘universal access’ health scheme to all temporary residents with HIV infection living legally in Australia, but currently deemed ineligible to access subsidised ART via this scheme.  

**Methods:** A mathematical model to estimate the number of new HIV infections averted and the associated lifetime costs over 5 years if all HIV-positive temporary residents in Australia had access to ART and subsidised medical care was developed. Input data came from a cohort of 180 HIV-positive temporary residents living in Australia who are receiving free ART donated by pharmaceutical companies for up to 4 years.  

**Results:** Expanding ART access to an estimated total 450 HIV+ temporary residents in Australia for 5 years could avert 80 new infections. The model estimated the total median discounted (5%) cost for ART and associated care to be A$36 million, while the total savings in lifetime-discounted costs for the new infections averted was A$22 million.  

**Conclusions:** It is estimated that expanded access to ART for all HIV-positive temporary residents in Australia will substantially reduce HIV transmission to their sexual partners at little additional cost. In the context of Australia’s National HIV strategy and Australia’s endorsement of global goals to provide universal access to ART for all people with HIV, this is an important measure to remove inequities in the provision of HIV-related treatment and care.

**Additional keywords:** antiretroviral therapy, Australia, HIV prevention, mathematical modelling, migrants, treatment access.

Received 19 December 2016, accepted 14 June 2017, published online 6 September 2017

**Introduction**

Effective antiretroviral treatment (ART) for HIV-positive (HIV+) individuals results in viral suppression leading to long-term disease remission, prolonged survival and the prevention of HIV transmission.\textsuperscript{1-8} Providing ART to infected individuals is a key prevention strategy and a crucial component of the HIV response internationally.\textsuperscript{8,10} Maintaining an undetectable viral load, however, requires regular access to care and treatment, with patients adhering to their treatment regimen.

The Australian government provides fully subsidised ART to HIV+ patients eligible for a Medicare card through the Pharmaceutical Benefits Scheme (PBS).\textsuperscript{11} Until they apply for residency, HIV+ temporary residents living in Australia are ineligible for a Medicare card and cannot access subsidised ART. Thus, most HIV+ temporary residents have limited options for accessing treatment and must pay the full cost of ART medications (with first-line regimens costing ~A$10 500 per year\textsuperscript{12}), source ART from their country of origin or import generic drugs from overseas suppliers. Such barriers prevent HIV+ temporary residents achieving optimal health outcomes and increase the risk of transmission to their sexual partners.\textsuperscript{13,14}

The Australian HIV Observational Database (AHOD) Temporary Residents Access Study (ATRAS) commenced in November 2011 and followed 180 HIV+ temporary residents in...
clinical and financial need of subsidised ART for 4 years.\textsuperscript{14,15} At enrolment, 63% of ATRAS patients were receiving ART from alternative sources, with only 70% having a suppressed viral load (<50 copies mL\textsuperscript{-1}); suggesting many were receiving suboptimal treatment. This percentage increased to 85% at 12-months follow up and to 96% at 24-months follow up. ATRAS only provided ART to the end of 2015 to a proportion of all HIV+ temporary residents who were ineligible for Medicare in Australia.\textsuperscript{14,15} Using data from ATRAS, we estimated the effect and potential costs of providing ART to all HIV+ temporary residents in Australia.

**Methods**

We used a risk equation model to estimate the annual number of new infections over the next 5 years in sexual partners of the estimated 400–500 HIV+ temporary residents currently living in Australia.\textsuperscript{14,15} The calculations used parameter values based on the characteristics of the ATRAS cohort patients at enrolment, at 12-months follow up and at 24-months follow up.\textsuperscript{14,15} For projections beyond the years of available data, we used the most recent data value available. For each parameter, we specified a range of values and then sampled 1000 parameter sets. All model parameter values with justifications are provided in Table 1. We repeated the calculations for each parameter set 20 times to account for stochastic variations. Results were obtained using summary statistics from all simulations. Total costs are in AUD and rounded to the nearest AS$10,000. We provide a detailed description of the model equations, assumptions, and input parameter values and reproducible code in an online repository.\textsuperscript{21} All the analyses and results were generated using R version 3.1.2 and associated packages.\textsuperscript{21}

**Model population**

For this analysis, we assumed the population of HIV+ temporary residents in Australia have the characteristics of people in ATRAS.\textsuperscript{14,15} We split the overall population into a male group of men who have sex with men (MSM) (which, for the purposes of this analysis, we assume are exclusively homosexual) and into a non-MSM group consisting of females and heterosexual males. We assumed the MSM population made up 40–60% of the overall HIV+ temporary resident population, as reported in ATRAS.\textsuperscript{14,15} We used this compartmentalisation of the population because partners of MSM are likely to be at higher risk of infection (we did not consider population differences in treatment coverage and adherence).

**Number of new infections caused by to HIV+ temporary residents**

To estimate new infections due to HIV+ temporary residents, we first calculated the probability of HIV transmission over time.\textsuperscript{20} Our calculation incorporates the annual probability for an untreated HIV+ person to transmit HIV to another person ($\beta$), the proportion of the population taking ART ($\theta$), the proportion taking ART with an undetectable viral load ($\phi$), and the efficacy of viral suppression on HIV transmission ($\psi_{\text{ART}}$; assumed to be 90–99%\textsuperscript{6–8}); this is given by the equation:

$$\beta' = (1 - \theta \phi \psi_{\text{ART}}) \beta.$$  \hspace{1cm} (1)

We used 2011–15 ATRAS data for the proportion of HIV+ temporary residents taking ART and the corresponding proportion with an undetectable viral load. By using the calculated probability for each year (Equation 1), we then estimated the number of new infections each year ($I$) using a binomial distribution and the estimated population size for HIV+ temporary residents ($N$); that is, $I \sim \text{Binom}(N, \beta')$. From Equation 1, for large $N$ and small $\beta'$, this is approximately equal to:

$$I = N(1 - \theta \phi \psi_{\text{ART}}) \beta.$$  \hspace{1cm} (2)

We estimated the annual probability that an untreated HIV+ person transmits HIV to another person ($\beta$) using a weighted average of the separate probabilities for HIV+ temporary resident MSM and non-MSM. As the number of new infections for temporary residents is unknown, we assumed the transmission probability for untreated HIV+ temporary residents equals the transmission probability for the overall untreated HIV+ population in Australia. Substituting estimates for the overall Australian population obtained from the 2014 HIV care and diagnosis cascade (with a 25% uncertainty range),\textsuperscript{22,16} we obtained a range in the transmission risk for non-MSM of 0.049–0.081 per year and 0.077–0.128 per year for MSM (Table 1). This estimate for $\beta$ implicitly includes behaviour affecting HIV transmission and the impact of current prevention programs. Our analysis then assessed the impact of ART and viral suppression, in addition to this background transmission.

The ATRAS cohort only provides clinical data and does not report behavioural data or sexual partner characteristics relevant to HIV transmission. Due to this lack of data, we were unable to develop a more detailed model of HIV transmission for HIV+ temporary residents. Thus, our analysis did not include additional infections due to transmission from newly infected partners (unless they are also temporary residents in which case they would become part of the HIV+ temporary resident population). Only infections directly attributed to HIV+ temporary residents were included. We also assumed HIV+ temporary residents on ART, but with unsuppressed virus, had the same annual transmission probability as untreated HIV+ temporary residents.

**Model scenarios**

To assess the impact of expanding ART access to all HIV+ temporary residents, we considered two modelling scenarios. First, we ran a ‘status quo’ scenario, where the proportion of HIV+ temporary residents virally suppressed remained constant and equalled the proportion at the start of ATRAS (58–68% on ART with 65–75% suppressed). We then ran an ‘expanded access’ scenario, where the proportion of the population taking ART and with suppressed virus changed over time to reach 90–100% of HIV+ temporary residents by 24 months, matching ATRAS data.\textsuperscript{14,15} For both scenarios, the annual probability an untreated HIV+ person transmits HIV to another person ($\beta$) retained the same value. This means the sexual behaviour
Based on the ATRAS data, we assume the percentage of temporary residents on ART increases from 70% to 95%, with a range of enrolment, all patients were put onto ART, resulting in 87% having an undetectable viral load at 12 months and 96% having an undetectable viral load at 24 months.

In both MSM and non-MSM taking ART, ~90% have an undetectable viral load. Putting these values into Equation 2 in the main text and assuming costs to range from A$3000 to A$5000. Using these values, we assumed a range in the annual ART cost (including medical care) of A$10 000 to A$20 000.

We are not tracking their infection progression in this analysis, we used an estimate for the lifetime cost of providing ART. An analysis of the life expectancy ~40 years, spending ~9 years on infection monitoring for HIV+ people with CD4 <200 cells mL⁻¹, CD4 >200–349 cells mL⁻¹, CD4 350–499 cells mL⁻¹, and CD4 >500 cells mL⁻¹ was estimated to cost A$3097, A$4402, A$4762 and A$7883 respectively. In recent years, patients in the Australian HIV Observational Database (AHOD) cohort have initiated ART at ~350 cells mL⁻¹ and the associated annual monitoring costs to range from A$3000 to A$5000. Using these values, we assumed a range in the annual ART cost (including medical care) of A$10 000 to A$20 000.

If a partner of a temporary resident becomes infected with HIV, then they will eventually require care and treatment while they are living in Australia. As we are not tracking their infection progression in this analysis, we used an estimate for the lifetime cost of providing ART. An analysis of the life expectancy of PLWHIV in Australia, given currently available antiretroviral treatments, suggests someone starting treatment in their twenties will be taking ART for ~40 years, spending ~9 years on first-line drugs, ~14 years on second-line drugs, ~3 years on third-line drugs, and the remainder of the time on higher classes of drug. Using the cost estimates from the study by Schneider et al., we assume the annual costs of proving each line of drugs is A$10 685 for first-
line drugs, A$19,364 for second-line drugs, A$31,411 for third-line drugs and A$28,162 for fourth and higher lines of drugs. Multiplying the values for each drug class and summing the resulting values produces the undiscounted treatment cost. To account for all uncertainties in the time patients are on each treatment class and drug costs, we assumed a range of ±25% in the overall undiscounted cost. Finally, we added the annual monitoring cost ranging from A$3,000 to A$5,000, as described in footnote 5 to produce the undiscounted cost presented here.

7. To discount future costs of providing ART to temporary residents and to those who become infected, we applied a discount rate of 5% from the year of enrolment in ATRAS for all treatment costs. For discounting purposes, we included the time between infection and initiating ART; we estimated this from data on the CD4 count at initiating therapy and estimates for the rate of CD4 decline. In recent years, participants in the AHOD cohort have initiated ART at ~350 cells μL⁻¹; it is estimated that it takes 4.4 years for a person to reach this CD4 count post infection. We therefore assume a range of 4–5 years for the time between infection and ART initiation.

| Table 2. Summary results for status quo scenario and the expanded access scenario |
|----------------------------------|-----------------|------------------|
| Indicator                        | Status quo scenario (median, IQR) | Expanded access scenario (median, IQR) |
| Annual infections after 5 years  | 22 (18–26)       | 5 (3–7)          |
| Cumulative infections            | 131 (116–145)    | 80 (68–91)       |
| Infections averted               | NA              | NA               |
| Cost of providing care and ART (undiscounted) | NA       | A$40,820,000 (A$34,110,000–A$47,530,000) |
| Lifetime care and ART costs (undiscounted) | A$313,620,000 (A$111,230,000–A$152,020,000) | A$80,570,000 (A$41,450,000–A$59,700,000) |
| Reduction in lifetime care and ART costs (undiscounted) | NA       | A$50,700,000 (A$65,840,000–A$95,310,000) |
| Cost of providing care and ART (discounted 5%) | NA       | A$36,240,000 (A$30,280,000–A$42,200,000) |
| Lifetime care and ART costs (discounted 5%) | A$36,640,000 (A$31,490,000–A$41,780,000) | A$12,300,000 (A$12,170,000–A$17,140,000) |
| Reduction in lifetime care and ART costs (discounted 5%) | NA       | A$21,730,000 (A$17,930,000–A$25,530,000) |

of temporary residents and the effects of current prevention strategies are maintained for both scenarios. Any change in new infections is then due to the change in treatment coverage and the level of viral suppression.

Costs associated with ART provision
At enrolment, nearly all ATRAS patients already on ART were taking ART drug combinations recommended in current ART treatment guidelines. We assumed all patients were on and continued to take recommended ART drug combinations over the analysis period and assumed a range in the annual cost of providing ART (including the cost of medical care) of A$10,000–A$20,000 based on previous work, as described in Table 1.

We estimated the ‘lifetime’ cost of providing care and treatment to sexual partners of temporary residents who become infected; this was based on the number of years a patient takes first, second, third and higher classes of drugs if they begin ART in their twenties. Using the cost estimates for each drug class in Australia with an assumed uncertainty of ±25% and adding annual medical care costs, gives a range in the undiscounted lifetime cost of providing ART post infection of $761,800–$1,269,700 (Table 1). We applied a discount rate of 5% to all treatment costs. For discounting purposes, we assumed a conservative time between infection and initiating ART of 4–5 years. Note that this time between becoming infected with HIV and initiating ART reflects the estimated time to reach the average CD4 count at which HIV+ temporary residents in ATRAS started treatment, and does not include the effect of changing guidelines for initiating ART (see footnote 7, Table 1).

To assess the sensitivity to this assumption, we also ran our analysis with a 2- to 4-year range in time between infection and initiating ART. This change produced only a minor increase (<10%) to our discounted cost estimates presented here, and did not affect the conclusions (the results of this analysis are available in the online repository).

Results
During the first year after providing ART to all HIV+ temporary residents, there were 22 (interquartile range (IQR): 18–26) new infections caused by HIV+ temporary residents (Fig. 1). Expanding ATRAS to all HIV+ temporary residents and achieving almost universal viral suppression reduced annual new infections to a median of 5 (IQR: 3–7) after 5 years (Table 2; Fig. 1). Providing treatment and care to all HIV+ temporary residents averted a median of 80 new infections (IQR: 68.5–91.5) over 5 years (Table 2; Fig. 2a), at a median undiscounted cost of A$40,820,000 (IQR: A$34,110,000–A$47,530,000) and a median discounted cost of A$36,640,000 (IQR: A$31,490,000–A$41,780,000) (taking the median of the sum for each simulation). This corresponds to a cost per infection averted of A$450,000 (IQR: A$360,000–A$540,000) (with 5% discounting). Figure 2b shows the cumulative costs for providing ART and subsidised care to this population for the next 5 years compared with the savings due to the reduction in infections during this
benefits of providing ART to temporary residents

Discussion

Our analysis showed that providing ART to HIV+ temporary residents within Australia will substantially reduce new infections and is unlikely to place a significant financial burden on the Australian Government — providing strong justifications for the provision of ART to temporary Australian residents. In our view, the only sustainable way to support optimal antiretroviral treatment for HIV+ temporary residents and achieve the resulting patient and population benefits over the long-term is through government subsidised ART. At the cessation of ATRAS in November 2015, 66 ATRAS patients and 400–500 HIV+ temporary residents nationally required an alternative mechanism for accessing ART. Pharmaceutical companies are currently providing access to antiretroviral treatment for Medicare ineligible patients on a compassionate basis in Australia. This is neither ideal nor sustainable. Applying for compassionate access is inefficient, time consuming for clinical staff, and delays treatment initiation. Numerous administrative barriers for specific treatments exist and not all antiretroviral drugs are available through compassionate access; this results in the use of suboptimal regimens instead of drugs, which are clinically indicated and medically appropriate. Furthermore, patients are often required to initially attempt sourcing ART from overseas, which leads to stress and further delays to achieving viral suppression. Overseas supplies of drugs are also often less safe and of lower quality. Finally, basing this important public health measure on the goodwill of commercial companies is subject to change, especially as generic antiretrovirals enter the Australian market from 2017. While the majority of HIV+ temporary residents within Australia eventually become permanent residents and eligible for ART under Medicare, results from the START trial24 and ATRAS14 show that any barriers and delays in treatment are detrimental to their health and are contrary to public health considerations.

Australia’s current National HIV Strategy aims to have 90% of all HIV+ people on ART and to virtually eliminate transmission by 2020.25 To achieve ambitious HIV and ART targets across Australia will require a maximum focus on vulnerable and marginalised populations like HIV+ temporary residents, and must ensure they have access to quality information, support, testing and ART.

Several analysis limitations affect the results. Most importantly, due to data for sexual and injecting behaviour, sexual partner characteristics and prevention practices being...
unavailable, we were unable to develop a more detailed model of HIV transmission among temporary residents in Australia. The only data source providing data for HIV+ temporary residents is the ATRAS study, which is a clinical cohort with no associated behavioural- or transmission-related data. This meant our calculations required several simplifying assumptions to estimate the risk of transmission. We assumed transmission parameters for treated and untreated patients are constant over time, whereas there is evidence the risk of transmission has been decreasing over the last 10 years.\(^2\)\(^3\) We also assumed, due to limited data for temporary residents, HIV transmission from untreated HIV+ temporary residents is the same as for the overall Australian population of people living with HIV. Temporary resident populations are often culturally and linguistically diverse, with less engagement with care and lower knowledge of HIV and prevention methods — suggesting they may have a higher risk of transmission to their partners.\(^2\)\(^6\)\(^–\)\(^8\) Due to a lack of data on the partners of temporary residents, we were unable to consider onward transmission from newly infected partners of temporary residents. These assumptions may result in an underestimate for the number of new infections prevented. Counteracting this, however, is the assumption those with unsuppressed virus have the same transmission risk as those not taking ART, whereas treatment is likely to still have some efficacy even if it does not completely suppress a patient’s viral load. In addition, the rate of partner change is constant due to an implicit homogenous mixing assumption, whereas many temporary residents could be in monogamous partnerships (and hence can only transmit HIV once) or have no sexual partners in Australia. Overestimating the number of new infections increases the cost-effectiveness of providing ART to the temporary resident population, while underestimating new infections decreases it. Finally, we also assumed partners of HIV+ temporary residents are Medicare eligible. This assumption likely lowers the cost of providing ART to HIV+ temporary residents, as some of their sexual partners may also be ineligible for Medicare.

By denying ART access to HIV+ temporary residents via Medicare, the Australian Government increases the risk of HIV transmission and the future long-term costs of providing HIV care and treatment, eroding any savings gained by denying HIV+ temporary residents access to subsidised treatment. The Australian Government already allows HIV+ temporary residents to live and work in Australia, and contribute economically through taxation. Providing these individuals with subsidised ART will cost little overall and help Australia achieve its National HIV Strategy targets.

Conflicts of interest

Bill Whittaker, Jo Watson, Lisa Bastian have no conflicts of interest. Kathy Petoumenos and Matthew Law’s institution have received an unrestricted research grant from Gilead Science. Kathy Petoumenos has conducted consultancy work for ViiV Healthcare. Richard Gray’s institution has received funding for his research from The World Bank Group, UNAIDS and NSW Department of Health. Jennifer Hoy’s institution has received funding for her participation on Advisory Boards for Merck Sharp & Dohme (Australia) Pty Ltd., Gilead Sciences Pty Ltd., ViiV Healthcare Pty Ltd. and Janssen-Cilag Pty Ltd. Don Smith has received research grants from Gilead Sciences Pty Ltd., ViiV Healthcare Pty Ltd., Merck Sharp & Dohme (Australia) Pty Ltd., Abbott Australasia Pty Ltd., Kirby institute, NSW Department of Health, and educational support from Gilead Sciences Pty Ltd., ViiV Healthcare Pty Ltd., Merck Sharp & Dohme (Australia) Pty Ltd., Boehringer Ingelheim Pty Ltd., Janssen-Cilag Pty Ltd., Gilead Sciences Pty Ltd., Merck Sharp & Dohme (Australia) Pty Ltd. and ViiV Pty Ltd. Fraser Drummond is currently employed by ViiV Healthcare Pty Ltd.

Acknowledgements

Richard Gray designed the model, conducted the analysis, and was the lead writer. Kathy Petoumenos and Matthew Law had the initial idea for this analysis and contributed to the model design and analysis plan. Kathy Petoumenos, Jo Watson, Aaron Cogle, Don Smith, Jennifer Hoy, Robert Finlayson, Fraser Drummond, Bill Whittaker, Matthew Law contributed to the ATRAS study on which the analysis was based and assisted with procurement of data. All authors contributed to data interpretation, writing of the manuscript, and approved the submitted manuscript.

This analysis was conducted with support from the Australian Government Department of Health and Ageing and the Australian National Health and Medical Research Council (1050874).

The Australian HIV Observational Database is funded as part of the Asia Pacific HIV Observational Database, a program of The Foundation for AIDS Research, amfAR, and is supported in part by grant No. U01-AI069907 from the USA National Institutes of Health (with funding provided by the National Institute of Allergy and Infectious Diseases, Eunice Kennedy Shriver National Institute of Child Health & Human Development and the National Cancer Institute) and by unconditional grants from Boehringer-Ingelheim Pty Ltd., Bristol-Myers Squibb Australia Pty Ltd., Gilead Sciences Pty Ltd., GlaxoSmithKline, Janssen-Cilag Pty Ltd., Merck Sharp & Dohme (Australia) Pty Ltd., Roche Pty Ltd. and Pfizer Pty Ltd. The Kirby Institute is funded by the Australian Government Department of Health, and is affiliated with the Faculty of Medicine, UNSW Sydney. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions mentioned above. AbbVie Pty Ltd, Boehringer Ingelheim Pty Ltd, Bristol-Myers Squibb Pty Ltd., Gilead Sciences Pty Ltd., Janssen-Cilag Pty Ltd., Merck Sharp & Dohme (Australia) Pty Ltd. and ViiV Healthcare Pty Ltd. provide ART on a compassionate basis to ATRAS patients via participating sites.

Both the National Association of People with HIV Australia (NAPWHA) and the ATRAS study partners acknowledge the people living with HIV organisations and networks across Australia supporting this work.

References


15 The Kirby Institute. The Australian HIV Observational Database Temporary Residents Access Study (ATRAS) One year follow-up. Sydney, NSW: The Kirby Institute, UNSW Australia; 2013.


